References
- Duthey B. Alzheimer’s Disease and Other Dementias. Background Paper. Report No.: 6.11. World Health Organization, 2013
- Dempsey L, Dowling M, Larkin P, et al. The unmet palliative care needs of those dying with dementia. Int J Palliat Nurs 2015;21:126-33, PMID: 2581576, Location: Ireland. Available from doi: 10.12968/ijpn.2015.21.3.126.
- Hughes JC, Robinson L, Volicer L. Specialist palliative care in dementia. BMJ 2005;330:57-8
- Miller SC, Mor V, Teno J. Hospice enrollment and pain assessment and management in nursing homes. J Pain Symptom Manage 2003;26:791-9
- Miller SC, Gozalo P, Mor V. Hospice enrollment and hospitalization of dying nursing home patients. Am J Med 2001;111:38-44
- Araw M, Kozikowski A, Sison C, et al. Does a palliative care consult decrease the cost of caring for hospitalized patients with dementia? Palliat Support Care 2015;13:1535-40
- Teno JM, Gozalo PL, Lee IC, et al. Does hospice improve quality of care for persons dying from dementia? J Am Geriatr Soc 2011;59:1531-6
- Miller SC, Lima JC, Mitchell SL. Influence of hospice on nursing home residents with advanced dementia who received Medicare-skilled nursing facility care near the end of life. J Am Geriatr Soc 2012;60:2035-41
- Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 2006;9:101-24
- American Psychiatric Association. Practice Guideline for the Treatment of Patients with Alzheimer’s Disease and Other Dementias, 2nd edn. Arlington, VA: American Psychiatric Association, 2007
- Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006;1:CD005593
- Rising Tide: The Impact of Dementia on Canadian Society. Report. Alzheimer Society of Canada, 2010, Location: Canada. Available from http://www.alzheimer.ca/~/media/Files/national/Advocacy/ASC_Rising_Tide_Full_Report_e.pdf [Accessed January 10, 2018].
- Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003;289:210-16
- Gauthier S, Patterson C, Chertkow H, et al. Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). Can Geriatr J 2012;15:120-6
- Daiello LA, Ott BR, Lapane KL, et al. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. Am J Geriatr Pharmacother 2009;7:74-83
- Parsons C. Withdrawal of antidementia drugs in older people: who, when and how? Drugs Aging 2016;33:545-56
- Herrmann N, O’Regan J, Ruthirakuhan M, et al. A randomized placebo-controlled discontinuation study of cholinesterase inhibitors in institutionalized patients with moderate to severe Alzheimer disease. J Am Med Dir Assoc 2016;17:142-7
- Bidzan L, Bidzan M. Withdrawal syndrome after donepezil cessation in a patient with dementia. Neurol Sci 2012;33:1459-61
- Singh S, Dudley C. Discontinuation syndrome following donepezil cessation. Int J Geriatr Psychiatry 2003;18:282-4
- Lee J, Monette J, Sourial N, et al. The use of a cholinesterase inhibitor review committee in long-term care. J Am Med Dir Assoc 2007;8:243-7
- Sadowsky CH, Dengiz A, Olin JT, et al. Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer’s disease. Am J Alzheimers Dis Other Demen 2009;24:267-75
- Grassi L, Caraceni A, Mitchell AJ, et al. Management of delirium in palliative care: a review. Curr Psychiatry Rep 2015;17:550,015-0550-8